News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

New Data for Incyte Corporation (INCY)'s Jakafi® (ruxolitinib) Presented at 2012 American Society of Clinical Oncology Annual Meeting


6/5/2012 10:20:02 AM

CHICAGO--(BUSINESS WIRE)--Incyte Corporation (Nasdaq: INCY) announced today that analyses from several clinical studies of Jakafi® (ruxolitinib) were presented at the 2012 American Society of Clinical Oncology Annual Meeting from June 1 to 5. Jakafi, an oral JAK1 and JAK2 inhibitor, is FDA-approved for the treatment of patients with intermediate or high-risk myelofibrosis (MF), and is the first and only product to be approved by the FDA for MF. Jakafi is also the first JAK inhibitor to be approved for any indication.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES